FDA Approval for Dexrazoxane Hydrochloride

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Brand name(s): Zinecard®, Totect™

Full prescribing information for Totect is available, including clinical trial information, safety, dosing, drug-drug interactions and contraindications.

Full prescribing information for Zinecard is available, including clinical trial information, safety, dosing, drug-drug interactions and contraindications.

Treatment of Extravasation Caused by Intravenous Anthracycline Chemotherapy

On September 6, 2007, the FDA approved dexrazoxane hydrochloride for injection (Totect™ made by TopoTarget USA, Inc.), equivalent to 500 mg dexrazoxane, for the treatment of extravasation resulting from intravenous anthracycline chemotherapy. Extravasion occurs when injected drugs leak out of the vein and into the skin.

In two studies, patients who were receiving single-agent anthracycline intravenously (usually as part of combination chemotherapy) and who developed extravasation symptoms of pain, burning, swelling, and redness near the infusion site received dexrazoxane hydrochloride to reduce surgical interventions for tissue injury following anthracycline extravasation. The protocol required extravasation to be confirmed by the presence of fluorescence in tissue biopsies.

The first dexrazoxane hydrochloride dose was given as soon as possible and within six hours following extravasation. After the first dose, treatment was repeated 24 and 48 hours later for a total of three doses. Dexrazoxane hydrochloride was administered as a 1-2 hour IV infusion through a different venous access location. The first and second doses were 1000 mg/m2 and the third dose was 500 mg/m2 up to a maximum daily dose of 2000 mg on days 1 and 2 and 1000 mg on the third day.

Extravasation was confirmed in 57 patients. The anthracyclines most commonly involved were epirubicin (56 percent) and doxorubicin (41 percent). Peripheral sites of extravasation included the forearm in 63 percent, the hand in 21 percent, and the antecubital area in 11 percent; four patients received the anthracycline via a central venous access device (CVAD). Most patients presented with swelling (83 percent), redness (78 percent), and pain (43 percent).

After dexrazoxane hydrochloride treatment, only one of the 57 patients required surgery. Thirteen patients had late adverse effects at the injection site such as pain, fibrosis, atrophy, and local sensory disturbance; all were judged as mild except in the one patient who required surgery. None of the four patients with CVADs required surgical intervention.

Dexrazoxane hydrochloride is a cytotoxic drug. When administered to patients receiving anthracycline-containing cytotoxic therapy, additive cytotoxicity may occur. Treatment with dexrazoxane hydrochloride is associated with leukopenia, neutropenia, and thrombocytopenia. Reversible elevations of liver enzymes may occur. Renal excretion is the primary metabolic pathway. Dimethylsulfoxide (DMSO) should not be used in patients who are receiving dexrazoxane to treat anthracycline-induced extravasation.


Treatment of Cardiomyopathy Caused by Doxorubicin

In May 1995, the U.S. Food and Drug Administration (FDA) approved dexrazoxane hydrochloride for injection (Zinecard®, made by Pfizer U.S. Pharmaceuticals) as a treatment to reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration in certain breast cancer patients.

  • Updated: July 2, 2013